格隆汇10月29日丨欧林生物(688319.SH)发布三季报，2025年前三季度实现营业总收入5.07亿元，同比增 长31.11%；归属母公司股东净利润4747.98万元，同比增长1079.36%；基本每股收益为0.1171元。 ...

Core Insights - The company reported a significant decline in revenue and a net loss for the first three quarters of 2025, indicating a challenging market environment [1] Financial Performance - The company achieved an operating revenue of 7.627 billion yuan, representing a year-on-year decrease of 66.53% [1] - The net profit attributable to shareholders was -1.206 billion yuan, marking a shift from profit to loss compared to the previous year [1] Reasons for Revenue Decline - The company attributed the decrease in revenue to underperformance in market sales, which did not meet expectations [1]

针对业绩变动的原因，欧林生物表示，由于年初至报告期末收入实现增长，同时管理费用有所下降。管 理费用减少，主要系上年同期发生了金额较大的试验及验证费用，而本期无此类大额支出所致。 北京商报讯（记者 丁宁）10月29日晚间，欧林生物（688319）发布2025年三季报显示，公司前三季度 营业收入5.07亿元，同比增长31.11%；归属净利润4747.98万元，同比增长1079.36%。 ...

Core Viewpoint - Hualan Biological reported a decline in both revenue and net profit for the first three quarters of 2025, indicating potential challenges in its financial performance [1] Financial Performance - The company achieved a revenue of 3.379 billion yuan, representing a year-on-year decrease of 3.2% [1] - The net profit attributable to shareholders was 784 million yuan, reflecting a year-on-year decline of 15.07% [1]

人民财讯10月29日电，智飞生物（300122）10月29日发布2025年三季报，公司第三季度营业收入27.05 亿元，同比下降40.26%；净利润亏损6.01亿元，上年同期亏损8369.64万元。2025年前三季度营业收入 76.27亿元，同比下降66.53%；净利润亏损12.06亿元，上年同期盈利21.51亿元。前三季度营业收入下降 主要是本期市场销售未达预期，收入减少。 ...

智飞生物公告，第三季度营收为27.05亿元，同比下降40.26%；净利润亏损6.01亿元，下降556.79%。前 三季度营收为76.27亿元，同比下降66.53%；净利润亏损12.06亿元，下降156.86%。 ...

每经头条（nbdtoutiao）——A股突破4000点！十年沉寂终迎爆发，科技主线重塑市场，"慢牛"新格局开 启！ 每经AI快讯，欧林生物（SH 688319，收盘价：24.03元）10月29日晚间发布三季度业绩公告称，2025年 前三季度营收约5.07亿元，同比增加31.11%；归属于上市公司股东的净利润约4748万元，同比增加 1079.36%。 截至发稿，欧林生物市值为98亿元。 （记者 张明双） ...

Core Viewpoint - Hualan Vaccine (301207.SZ) reported a decline in revenue and net profit for the first three quarters of 2025, indicating potential challenges in its financial performance [1] Financial Performance - The company's operating revenue for the first three quarters was 806 million yuan, a year-on-year decrease of 15.81% [1] - The net profit attributable to shareholders was 132 million yuan, reflecting a year-on-year decrease of 50.51% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 86.26 million yuan, down 56.02% year-on-year [1] - Basic earnings per share were 0.2224 yuan [1]

欧林生物公告，第三季度营收为2.01亿元，同比增长25.38%；净利润为3428.29万元，同比增长7.22%。 前三季度营收为5.07亿元，同比增长31.11%；净利润为4747.98万元，同比增长1,079.36%。 ...

Core Viewpoint - Hualan Vaccine (301207.SZ) reported a significant decline in revenue and net profit for the first three quarters of 2025 compared to the previous year [1] Financial Performance - The company achieved an operating income of 806 million yuan, representing a year-on-year decrease of 15.81% [1] - The net profit attributable to shareholders was 132 million yuan, down 50.51% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 86.26 million yuan, a decrease of 56.02% year-on-year [1] - Basic earnings per share were reported at 0.2224 yuan [1]